You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 5,484,926


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,484,926
Title: HIV protease inhibitors
Abstract:HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
Inventor(s): Dressman; Bruce A. (Indianapolis, IN), Fritz; James E. (Greenwoode, IN), Hammond; Marlys (Pasadena, CA), Hornback; William J. (Indianapolis, IN), Kaldor; Stephen W. (Indianapolis, IN), Kalish; Vincent J. (San Diego, CA), Munroe; John E. (Indianapolis, IN), Reich; Siegfried H. (San Diego, CA), Tatlock; John H. (Poway, CA), Shepherd; Timothy A. (Indianapolis, IN), Rodriguez; Michael J. (Indianapolis, IN)
Assignee: Agouron Pharmaceuticals, Inc. (San Digeo, CA)
Application Number:08/190,764
Patent Claim Types:
see list of patent claims
Compound;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 5,484,926

Introduction

United States Patent 5,484,926, hereafter referred to as the '926 patent, is a significant patent that has contributed to the intellectual property landscape in its respective field. To understand its impact and the broader patent landscape, it is crucial to delve into its scope, claims, and the context in which it was granted.

Background of the Patent

The '926 patent was granted by the United States Patent and Trademark Office (USPTO) and is part of the extensive database of patents that have shaped various industries. Patents like this one are protected under the U.S. patent law, which grants the holder exclusive rights to make, use, sell, or import the invention in the United States until the patent expires[1].

Eligible Subject Matter Requirement

For a patent to be valid, it must satisfy the eligible subject matter requirement. This means the invention must be a new and useful "process, machine, manufacture, or composition of matter, or any improvement thereof"[1]. The '926 patent would have been scrutinized to ensure it falls within these categories and does not claim ineligible subject matter such as laws of nature, natural phenomena, or abstract ideas.

Novelty and Nonobviousness Requirements

Two fundamental requirements for patentability are novelty and nonobviousness. The claimed invention must be novel, meaning it was not patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[1]. Additionally, the invention must be nonobvious, meaning it would not have been obvious to a person having ordinary skill in the relevant field at the time of the invention[1].

Claims of the Patent

The claims of a patent define the scope of the invention and are critical in determining what is protected. The '926 patent would have multiple claims, each detailing a specific aspect of the invention. These claims are categorized into independent and dependent claims, with independent claims standing alone and dependent claims referring back to one or more of the independent claims[3].

Patent Landscape

The patent landscape surrounding the '926 patent includes other related patents and prior art. The USPTO's Patent Public Search tool and the Global Dossier service can be used to identify related applications and prior art, helping to understand the broader context in which the '926 patent was granted[4].

Challenges and Validity

The validity of the '926 patent can be challenged through administrative proceedings such as Inter Partes Review (IPR) or Post-Grant Review (PGR) before the Patent Trial and Appeal Board (PTAB). These proceedings allow anyone to challenge the patent on grounds that it fails to meet the requirements for patentability, such as novelty, nonobviousness, or eligible subject matter[1].

Economic and Practical Impact

The economic impact of a patent like the '926 patent can be significant. Patents can drive innovation by providing a monopoly to the inventor, encouraging the disclosure of inventions. However, they can also impede innovation if they are overly broad or if they claim ineligible subject matter. The USPTO's economic research datasets can provide insights into the economic impact of patents and their scope[3].

Small Claims Patent Court Considerations

In recent years, there has been discussion about the feasibility of a small claims patent court to handle disputes involving smaller entities or less complex patent issues. Such a court could potentially affect the landscape for patents like the '926 patent by providing a more accessible and cost-effective forum for resolving patent disputes[2].

Search and Analysis Tools

To conduct a detailed analysis of the '926 patent, several tools are available:

  • Patent Public Search: This tool provides enhanced access to prior art and allows for a comprehensive search of existing patents and published patent applications[4].
  • Global Dossier: This service allows users to see the patent family for a specific application, including related applications filed at participating IP Offices, along with the dossier, classification, and citation data[4].
  • Patent Claims Research Dataset: This dataset contains detailed information on claims from U.S. patents and can be used to analyze the scope and claims of the '926 patent[3].

Key Takeaways

  • Scope and Claims: The '926 patent's scope and claims are defined by its independent and dependent claims, which must meet the requirements of eligible subject matter, novelty, and nonobviousness.
  • Patent Landscape: Understanding the broader patent landscape involves identifying related patents and prior art using tools like the Patent Public Search and Global Dossier.
  • Challenges and Validity: The validity of the '926 patent can be challenged through PTAB proceedings such as IPR or PGR.
  • Economic Impact: Patents like the '926 patent can have significant economic impacts, driving innovation but also potentially impeding it if not properly scoped.
  • Small Claims Court: The concept of a small claims patent court could change how patent disputes are resolved, making it more accessible for smaller entities.

FAQs

Q: What are the key requirements for a patent to be valid in the United States? A: A patent must meet the requirements of eligible subject matter, novelty, and nonobviousness.

Q: How can the validity of a patent be challenged? A: The validity of a patent can be challenged through administrative proceedings such as Inter Partes Review (IPR) or Post-Grant Review (PGR) before the Patent Trial and Appeal Board (PTAB).

Q: What tools are available for searching and analyzing patents? A: Tools such as the Patent Public Search, Global Dossier, and Patent Claims Research Dataset are available for searching and analyzing patents.

Q: Why is the concept of a small claims patent court being discussed? A: The concept is being discussed to provide a more accessible and cost-effective forum for resolving patent disputes, particularly for smaller entities.

Q: How does a patent impact the economy? A: A patent can drive innovation by providing a monopoly to the inventor, encouraging the disclosure of inventions, but it can also impede innovation if it is overly broad or claims ineligible subject matter.

Sources

  1. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review," Updated May 28, 2024.
  2. Administrative Conference of the United States, "U.S. Patent Small Claims Court."
  3. United States Patent and Trademark Office, "Patent Claims Research Dataset."
  4. United States Patent and Trademark Office, "Search for patents - USPTO."

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 5,484,926

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 5,484,926

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 600 ⤷  Subscribe
African Regional IP Organization (ARIPO) 9600844 ⤷  Subscribe
Austria 222240 ⤷  Subscribe
Austria 286025 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.